NeoGenomics (NASDAQ:NEO) Releases FY 2025 Earnings Guidance

NeoGenomics (NASDAQ:NEO) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.150-0.190 for the period, compared to the consensus estimate of 0.200. The company issued revenue guidance of $735.0 million-$745.0 million, compared to the consensus revenue estimate of $735.0 million.

NeoGenomics Stock Down 2.0 %

Shares of NASDAQ NEO opened at $9.95 on Thursday. The firm has a 50 day moving average price of $14.06 and a 200 day moving average price of $15.11. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The stock has a market cap of $1.28 billion, a P/E ratio of -16.20 and a beta of 1.23. NeoGenomics has a 52-week low of $8.98 and a 52-week high of $19.11.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. Analysts expect that NeoGenomics will post -0.2 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NEO shares. The Goldman Sachs Group lowered their price target on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Jefferies Financial Group started coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target for the company. Needham & Company LLC decreased their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Piper Sandler dropped their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, Bank of America cut their target price on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $19.60.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.